Komori
Other Disclosures4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of Platinum Kurumin Plus Certification

Subsidiary Asuka Pharmaceutical obtained certification under the Ministry of Health, Labour and Welfare’s “Platinum Kurumin Plus” program for support in balancing work with childcare and fertility treatment.

Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

Platinum Kurumin Plus certification
Applicable field (uses covered by this announcement)

Childcare support, support for balancing work with fertility treatment, and workplace environment improvements

Launch date31 March 2026 (certification obtained)
What the company reported numerically
Quantitative Effects

Target parental leave uptake rate of 100% (target)

Relationship between the counterparty and the company
ASKA Pharmaceutical Holdings Co.,Ltd.4886
Relationship with the Company

Relationship between the certification recipient and the certifying body

CounterpartyTokyo Labour Bureau of the Ministry of Health, Labour and Welfare

The Tokyo Labour Bureau of the Ministry of Health, Labour and Welfare. Other details: Not disclosed

Award/certification name

Platinum Kurumin Plus certification

Awarding / certifying body

Tokyo Labour Bureau of the Ministry of Health, Labour and Welfare

Location (as indicated in this announcement)

Asuka Pharmaceutical head office: Minato-ku, Tokyo

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Special certification program under the Act on Advancement of Measures to Support Raising Next-Generation Children

Announced details
ItemDetails
Names of Products / Services CoveredPlatinum Kurumin Plus certification
CounterpartyTokyo Labour Bureau of the Ministry of Health, Labour and Welfare
Counterparty overviewThe Tokyo Labour Bureau of the Ministry of Health, Labour and Welfare. Other details: Not disclosed
Relationship with the CompanyRelationship between the certification recipient and the certifying body
Launch date31 March 2026 (certification obtained)
Applicable areaChildcare support, support for balancing work with fertility treatment, and workplace environment improvements
Award/certification namePlatinum Kurumin Plus certification
Awarding / certifying bodyTokyo Labour Bureau of the Ministry of Health, Labour and Welfare
LocationAsuka Pharmaceutical head office: Minato-ku, Tokyo
Quantitative EffectsTarget parental leave uptake rate of 100% (target)
SourceSpecial certification program under the Act on Advancement of Measures to Support Raising Next-Generation Children
Items this document does not state (7)
Contract ValueOffering priceContract DateRegistration number and expiry dateLocation scaleUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company met the certification criteria after its initiatives, including establishing childcare support and work-and-fertility-treatment support programs, a work support incentive program, and internal training, were recognized.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Platinum Kurumin Plus Certification | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori